PIOGLITAZONE
Generic: PIOGLITAZONE
Solco Healthcare LLCManufacturer
ORALRoute
PIOGLITAZONEActive Substance
2018-04-17Original Approval
PIOGLITAZONE is FDA application ANDA207806, sponsored by PRINSTON. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class II2019-09-23
Pioglitazone Hydrochloride Tablets USP 15 mg, 30 count bottles, Rx only, Manufactured for: Macleods Pharma USA, Inc., PlSuperpotent
Class II2021-12-29
Pioglitazone Tablets USP, 45 mg, 500 count bottles, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ -- NDC Superpotent and Failed Tablet/Capsule Specifications
Class III2020-01-24
Pioglitazone and Metformin Hydrochloride Tablets, USP 15 mg/500 mg, Rx Only, 60-count bottle, Manufactured for Macleods Subpotent Drug: Out of specification assay result, below specification, for two lots of Pioglitazone
Top Reported Reactions
1
NAUSEA
646 reports
2
DIARRHOEA
631 reports
3
FATIGUE
555 reports
4
DRUG INEFFECTIVE
542 reports
5
DYSPNOEA
461 reports
6
VOMITING
448 reports
7
BLOOD GLUCOSE INCREASED
440 reports
8
OFF LABEL USE
432 reports
9
ACUTE KIDNEY INJURY
385 reports
10
DIZZINESS
370 reports